PRAME and undifferentiated pleomorphic sarcoma: In the present study, we found PRAME expression in undifferentiated pleomorphic sarcoma (UPS), malignant peripheral nerve sheath tumour (MPNST), synovial sarcoma, leiomyosarcoma (LMS), angiosarcoma, dedifferentiated liposarcoma (DDLPS), uterine carcinosarcoma, and rhabdomyosarcoma, making PRAME a potential target for immunotherapy in these histological subtypes.